RxDoctor Payments Data

Brittney Benjamin, MD

Family Medicine · Sarasota, FLNPI 1578097895

Payments from drug & device makers

$1,313in general payments, 2019–2025

Across 46 payments — averaging $28.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$329
  • Novo Nordisk$193
  • Johnson & Johnson$149
  • AstraZeneca$142
  • Biohaven Pharmaceutical Holding Company Ltd.$128
  • Exact Sciences$114
  • plus $258 from 6 others

What the payments were for

  • Food & beverage$1,313100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,313 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$67,109
Medicare patients
292
Services billed
1,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$38,085
EliquisApixaban30$36,520
JanuviaSitagliptin Phosphate17$25,743
TrulicityDulaglutide12$19,401
MyrbetriqMirabegron14$12,814
SynthroidLevothyroxine Sodium56$4,111
Estradiol31$2,735
Levothyroxine Sodium252$2,667
Atorvastatin Calcium229$2,018
Rosuvastatin Calcium196$1,837
Gabapentin58$1,739
Omeprazole137$1,682
Duloxetine Hcl35$1,622
Memantine Hcl22$1,509
Ezetimibe47$1,479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$193$38,08517 claims
PfizerEliquis$16$36,52030 claims
MerckJanuvia$75$25,74317 claims
Lilly USA, LLCTrulicity$329$19,40112 claims
AbbVieSynthroid$88$4,11156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →